Lilly's experimental colitis drug posts positive Phase 2 data

Lilly's experimental colitis drug posts positive Phase 2 data

Source: 
Biopharma Dive
snippet: 

Eli Lilly's experimental antibody mirikizumab led to higher rates of clinical response and remission in patients with ulcerative colitis treated in a mid-stage study, which the pharma touted as the first public presentation of data from a IL-23p19 monoclonal antibody in the inflammatory condition.